Back to Agenda
Session 1 Biosimilars and Non-Originator Biologics (NOBs) Market Developments
Session Chair(s)
Steffen Thirstrup, MD, PHD
Chief Medical Officer, European Medicines Agency, Netherlands
Biosimilar market is developing both in Europe and globally with an increasing demand for biotherapeutics. The first biosimilar was approved in the EU in 2006 and FDA approved the first in in the US in early March this year. The session looks into the trends in different regions over the past years and also discusses the market access and pricing.
Speaker(s)
Per Troein, MBA, MSC
VP Strategic Partners, IQVIA, United Kingdom
Global Market Development of Biosimilars and Non-Originator Biologics in Emerging Markets
Hilda Juhász
Policy Officer, European Commission, Belgium
Outcome of the October EC workshop on Access to and Uptake of Biosimilars
Pieter Dylst, DrPH, MPHARM, RPH
Senior Manager Market Access & Value Added Medicines, Medicines For Europe, Belgium
European Generics and Biosimilar Medicines Association's view on market developments
Alexander Roediger, MA, MBA
Executive Director EMEAC Oncology Policy, MSD Sharp and Dohme GmbH, Switzerland
European Biopharmaceutical Enterprises and EFPIA's view on market developments
Have an account?